FDA advisory committee to review Novavax’s COVID-19 vaccine candidate in June

Shares of Novavax Inc. jumped 10.8% in trading on Friday after the Food and Drug Administration announced that an advisory committee is set to meet June 7 to examine the benefits and risks of the company’s experimental COVID-19 vaccine. Novavax’s protein-based vaccine has been authorized in several countries, including by the U.K. and the European Commission, but is still being reviewed by the FDA. The company’s stock has tumbled 65.6% this year, while the broader S&P 500 is down 10.0%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.